Background: BRAF mutations are frequent in melanoma but their prognostic significance remains unclear.
Objective: We sought to further evaluate the prognostic value of BRAF mutations in localized cutaneous melanoma.
Methods: We undertook an observational retrospective study of 147 patients with localized invasive (stages I and II) cutaneous melanomas to determine the prognostic value of BRAF mutation status.
Results: After a median follow-up of 48 months, patients with localized melanomas with BRAF-mutant melanomas exhibited poorer disease-free survival than those with BRAF-wt genotype (hazard ratio 2.2, 95% confidence interval 1.1-4.3) even after adjustment for Breslow thickness, tumor ulceration, location, age, sex, and tumor mitotic rate.
Limitations: The retrospective design and the small number of events are limitations.
Conclusions: Our findings suggest that reappraisal of clinical treatment approaches for patients with localized melanoma harboring tumors with BRAF mutation might be warranted.
Keywords: BRAF; NRAS; localized; melanoma; prognosis; survival.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.